Results 31 to 40 of about 22,708 (195)

TRAIP Mediates Alcohol‐Induced Liver Injury through Regulating β‐catenin Ubiquitin Degradation via Direct Interaction

Advanced Science, EarlyView.
This study reveals that NF‐κB1‐driven TRAIP upregulation in ALD correlates with disease severity. Mechanistically, TRAIP directly binds β‐catenin via its CC domain and promotes its K48‐linked ubiquitination and degradation, which is independent of the GSK3β/β‐TrCP pathway.
Zhan Wu, Mingjiang Liu, Lijuan Liao, Zhaohong Mo, Wenli Xu, Linfeng Mao, Yubing Chen, Qiuli Xie, Ming Yao, Shilian Chen, Stephen Tomlinson, Sebastian Mueller, Songqing He, Guandou Yuan   +13 more
wiley   +1 more source

EphB1‐Mediated Transient Blood‐Brain Barrier Opening Facilitates a Ferritin‐Based Nanotherapeutic for Alzheimer's Disease

Advanced Science, EarlyView.
We constructed a brain‐targeted AFn‐DPZ nanodrug delivery system and identified EphB1 as its receptor on the blood‐brain barrier (BBB). This system facilitates drug transport across the BBB and thereby ameliorates cognitive impairment in Alzheimer's disease.
Shilin Wen, Jingjing Gao, Zhixian Wang, Qiumin Ma, Xiao‐Ling Xu, Jianer Chen   +5 more
wiley   +1 more source

Innovative Test Strip‐Based Colorimetric Sensors Integrated With Affinity Chromatography: Acetylcholinesterase Inhibitor Screening Breakthrough in Lycium Barbarum Leaves

Advanced Science, EarlyView.
Schematic diagrams illustrating the breakthrough in the screening of AChE inhibitors from LBL, and the research process of the pharmacodynamics of the NCP are presented. ABSTRACT Current Alzheimer's drugs exhibit limited effectiveness, highlighting the necessity for multi‐target treatments.
Yuping Sa, Hui Yuan, Jingui Ma, Zhigang Yang, Mei Wang, Weibiao Wang, Lingling Yang, Fen Ma, Weiman Zhang, Gidion Wilson Mening'oo, Guoning Chen, Xueqin Ma   +11 more
wiley   +1 more source

Early Spatial and Contextual Coding Deficits in Hippocampal CA1 Precede Performance Decline in an Alzheimer's Disease Model

Advanced Science, EarlyView.
Two‐photon calcium imaging in behaving 5xFAD mice reveals early CA1 coding deficits before behavioral decline. Task‐related place cell activity and splitter cell trajectory coding are impaired, with reduced retrospective dominance and greater prospective weighting.
Yimei Li, Mary Ann Go, Hualong Zhang, Robertas Aleksynas, Juliana Kim, Mingyang Gao, Seigfred Prado, Magdalena Sastre, Simon R. Schultz   +8 more
wiley   +1 more source

Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.

PLoS ONE, 2014
Patients with Alzheimer's disease after an initial response to cholinesterase inhibitors may complain a later lack of efficacy. This, in association with incident neuropsychiatric symptoms, may worsen patient quality of life.
Gianfranco Spalletta, Carlo Caltagirone, Alessandro Padovani, Sandro Sorbi, Mahmood Attar, Delia Colombo, Luca Cravello, E V O L U T I O N study Working Group   +7 more
doaj   +1 more source

The effects of novel 7-MEOTA-donepezil like hybrids and N-alkylated tacrine analogues in the treatment of quinuclidinyl benzilate-induced behavioural deficits in rats performing the multiple T-maze test

Biomedical Papers, 2015
Aims: The number of approved drugs for the clinical treatment of Alzheimer disease remains limited. For this reason, there is extensive search for novel therapies.
Jan Misik, Jan Korabecny, Eugenie Nepovimova, Pavla Cabelova, Jiri Kassa   +4 more
doaj   +1 more source

Temporal‐Targeted Accelerated 40 Hz tACS Enhances Cognitive Function and Network Integration in Alzheimer's Disease: A Randomized Clinical Trial

Advanced Science, EarlyView.
Bilateral temporal accelerated 40‐Hz tACS improves cognitive function in patients with Alzheimer's disease. Resting‐state fNIRS identifies treatment‐related increases in frontotemporoparietal functional connectivity, which are associated with cognitive improvement. ABSTRACT The temporal lobes are key hubs for memory and cognition.
Rong Guo, Xingxing Li, Chenjun Zou, Chao Zheng, Xiaohong Wu, Xuechao Lu, Jiaying Yan, Junfang Zhang, Xiaoyan Luo, Shiwei Ye, Dongsheng Zhou   +10 more
wiley   +1 more source

In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor

Scientific Reports, 2023
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is growing rapidly among the elderly population around the world.
Asma Gholami, Dariush Minai-Tehrani, Leif A. Eriksson   +2 more
doaj   +1 more source

Synthesis and biological evaluation of lycorine derivatives as dual inhibitors of human acetylcholinesterase and butyrylcholinesterase

Chemistry Central Journal, 2012
Background Alzheimer’s disease (AD) is a neurologically degenerative disorder that affects more than 20 million people worldwide. The selective butyrylcholinesterase (BChE) inhibitors and bivalent cholinesterase (ChE) inhibitors represent new treatments ...
Wang Yue-Hu, Wan Qin-Li, Gu Cheng-Ding, Luo Huai-Rong, Long Chun-Lin   +4 more
doaj   +1 more source

CHOLINESTERASE INHIBITORS IN THE TREATMENT OF DEMENTIA ALZHEIMER’S

e-Jurnal Medika Udayana, 2013
Dementia is the loss of intellectual abilities which include decreased ability to think, remember,understand, calculate, concentrate, and find the right words. The causes of dementia areAlzheimer’s, vascular dementia, alcohol.
Prameidya Primaniar S
doaj